Source comparison
BPC-157 Intestinal Permeability: Dosing and Administration Comparison
Subcutaneous injection 250–500mcg daily 24–48 hours 90–95% (bypasses first-pass metabolism) Acute mucosal damage, post-NSAID ulceration, active IBD flare Highest tissue concentration; most consistent clinical response in veterinary and human case reports Oral
This comparison does not assign a generated winner or score.
- Subcutaneous injection
- 250–500mcg daily
- 24–48 hours
- 90–95% (bypasses first-pass metabolism)
- Acute mucosal damage, post-NSAID ulceration, active IBD flare
- Highest tissue concentration; most consistent clinical response in veterinary and human case reports
- Oral (standard capsule)
- 500–1000mcg twice daily
- 3–5 days
- 10–20% (degraded by gastric acid and proteases)
- Maintenance after initial repair; mild permeability without active inflammation
- Requires significantly higher doses; effectiveness varies widely by gastric pH and digestive enzyme activity
- Oral (enteric-coated)
- 500mcg twice daily
- 2–3 days
- 40–60% (protected until small intestine release)
- Preferred for intestinal-specific targeting; reduces gastric degradation
- Balances convenience with efficacy; most practical for long-term protocols
- Intraperitoneal (research)
- 10mcg/kg daily
- 12–24 hours
- Near 100%
- Not applicable to humans; used in rodent studies only
- Provides strongest preclinical data but doesn't translate to home administration
- The table underscores a critical point: effective BPC-157 dosing for intestinal permeability depends entirely on administration route. A 250mcg subcutaneous dose delivers more active peptide to the intestinal mucosa than 1000mcg taken orally without enteric protection. This is why comparing anecdotal reports without specifying route leads to confusion. One person reports dramatic improvement at 500mcg daily (subcutaneous), another reports zero effect at the same dose (oral standard capsule).